Spero Therapeutics Future Growth

Future criteria checks 3/6

Spero Therapeutics's revenue is forecast to decline at 13.4% per annum while its annual earnings are expected to grow at 40.4% per year. EPS is expected to grow by 35.2% per annum.

Key information

40.4%

Earnings growth rate

35.2%

EPS growth rate

Biotechs earnings growth42.7%
Revenue growth rate-13.4%
Future return on equityn/a
Analyst coverage

Low

Last updated18 Nov 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:2HA - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20266-25-23-222
12/31/202518-42N/A-473
12/31/202433-72N/A-462
9/30/20241064-18-18N/A
6/30/202411817-14-14N/A
3/31/202411123-14-14N/A
12/31/202310423-33-33N/A
9/30/202378-22929N/A
6/30/202354-101212N/A
3/31/202354-2788N/A
12/31/202254-46-8-8N/A
9/30/20229-102-80-80N/A
6/30/202210-113-84-84N/A
3/31/202213-103-77-77N/A
12/31/202118-90-64-64N/A
9/30/202117-79-53-53N/A
6/30/202118-76-70-70N/A
3/31/202115-74-78-78N/A
12/31/20209-79-86-86N/A
9/30/202011-85-87-87N/A
6/30/202012-84-75-75N/A
3/31/202012-80-63-62N/A
12/31/201918-61-50-50N/A
9/30/201916-47-49-46N/A
6/30/201912-39-45-42N/A
3/31/201911-36-41-39N/A
12/31/20184-42-42-40N/A
9/30/20183-46-39-39N/A
6/30/20183-47N/A-44N/A
3/31/20183-50N/A-44N/A
12/31/20172-46N/A-39N/A
9/30/20171-40N/A-36N/A
6/30/20171-35N/A-32N/A
3/31/20170-30N/A-29N/A
12/31/20160-30N/A-29N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 2HA's forecast earnings growth (40.4% per year) is above the savings rate (1%).

Earnings vs Market: 2HA's earnings (40.4% per year) are forecast to grow faster than the German market (20.9% per year).

High Growth Earnings: 2HA's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 2HA's revenue is expected to decline over the next 3 years (-13.4% per year).

High Growth Revenue: 2HA's revenue is forecast to decline over the next 3 years (-13.4% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 2HA's Return on Equity is forecast to be high in 3 years time


Discover growth companies